Release date: 2025-02-24 10:05:47 Article From: Lucius Laos Recommended: 115
Cabozantinib is a multi-kinase inhibitor that has shown significant efficacy in the treatment of a variety of tumors, but its use comes with a number of caveats.
Understanding the precautions for using cabozantinib is essential to ensure the safety and efficacy of treatment.
The dosage of cabozantinib is determined by the physician on a case-by-case basis and is usually taken on an empty stomach to maximize drug absorption. Patients should strictly follow the doctor's instructions, take the medication on time and in the right amount, and avoid increasing or decreasing the dose or changing the time of medication.
Cabozantinib may interact with other medications, affecting its effectiveness or increasing side effects. While using cabozantinib, patients should inform their doctor of all medications they are taking, including prescription drugs, over-the-counter medications, supplements, etc., so that the doctor can assess the potential risk of interactions.
A variety of adverse reactions may occur during cabozantinib treatment, such as hypertension, hand-foot syndrome, diarrhea, fatigue, etc. Patients should pay close attention to their physical condition, and if they develop uncomfortable symptoms, they should seek medical attention immediately and inform their doctor that they are using cabozantinib so that they can adjust their treatment regimen in time.
The use of cabozantinib should be as recommended for specific patient populations.
Hepatic and renal insufficiency may affect the metabolism and excretion of cabozantinib, thereby increasing the risk of drug accumulation. These patients should undergo liver and kidney function assessment before taking cabozantinib and, if necessary, dose adjustment or other treatment measures.
Older patients may be less tolerable to cabozantinib, so special attention should be paid to dose selection and adverse effect monitoring when using it. Doctors may need to develop a personalized treatment plan based on factors such as the patient's age, weight, liver and kidney function, etc.
Cabozantinib may cause adverse effects on the mother and fetus and should be avoided by pregnant women. Breastfeeding women should stop breastfeeding while using cabozantinib to avoid the drug being passed to the baby through breast milk.
Cabozantinib is an antineoplastic drug, and its use should be strictly followed by the doctor's instructions, paying attention to the dose and timing of medication, drug interactions, adverse reaction monitoring, and recommendations for use in special patient groups. Through scientific and rational use, the therapeutic effect of cabozantinib can be maximized, while the potential risk can be reduced, bringing a better treatment experience to patients.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: